Neuraxis Inc (NRXS) Noticias

$NRXS this is a massively strong buy right now.

Tested lowest support now let’s start back up

5.16 thin on the ask heading into the close!

$NRXS

NeurAxis Highlights Strength of its Board of Directors
https://finance.yahoo.com/news/neuraxis-highlights-strength-board-directors-130000862.html

$NRXS Closed strong at $6.01. Think we can see $7+ by the EOW... $14 price target here... $30B+ Total Addressable U.S. Market for Pipeline Indications.. Looking good!

$NRXS $30B+ Total Addressable U.S. Market for Pipeline Indications‼️

$9B+ Pediatric Addressable Market
$21B+ Adult Market

Bet we get nice continuation tomorrow $NRXS

NRXS In 13 Children's Hospital Sites. NRXS's focus is on the $9B pediatric market, for which no FDA cleared products exist and utilize the Company’s PENFS technology.

Looking for a move above $6 this week

Bid getting stronger here...

Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published independent studies showing that IB-Stim therapy leads to improvements in abdominal pain and disability in adolescents with IBS and that the gut microbiome may play an important role.

The publications, “The microbiome in adolescents with irritable bowel syndrome and changes with percutaneous electrical nerve field stimulation1,” authored by Daniel F. Castillo, et al, and “Impact of auricular percutaneous electrical nerve field stimulation on gut microbiome in adolescents with irritable bowel syndrome: a pilot study2,” authored by Geetanjalo Bora, et al, both highlight the effect of the gut microbiome in the treatment of adolescents with IBS using IB-Stim, NeurAxis’s proprietary technology.

$NRXS News Out➡️ NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome


#neuromodulation #FDA #Pediatric #FAP #IBS $MDT $CYBX $STJ $BSX $VIRI $JNJ $AMC

https://finance.yahoo.com/news/neuraxis-highlights-two-independent-studies-130000996.html

It wont take much volume to move this one

$14 price Target by Rob Goldman

$NRXS huge breakout coming soon, super thin on the ask! https://www.youtube.com/@ib-stim

Thanks, great technology here with $NRXS

$NRXS Check it out. Love the cutting-edge tech here. This is a small explainer video on how the Company is targeting a 9 Billion Dollar market. http://primetimeprofiles.com/web-stories/neuraxis/

$NRXS NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
https://ir.neuraxis.com/news-releases/news-release-details/neuraxis-announces-over-8-million-ib-stimtm-revenue

08/17/23
CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. NeurAxis is conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.

Approximately $2 million of the over $8 million in IB-Stim™ revenue through March 31, 2023 was generated in 2020 and 2019.

Brian Carrico, Chief Executive Officer of NeurAxis, said, “We are pleased to have reached over $8 million in sales of our proprietary IB-Stim™ technology and look forward building upon our momentum with the funds received from our recently completed IPO. We continue to drive increasing adoption of our IB-Stim™ therapy, supported by a significant and growing body of positive clinical data and commercial large health insurance company payor support. We believe the growing movement of patients gravitating towards non drug related therapies, especially for children, will continue to fuel our rapidly increasing adoption and the market for our new indications.”

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

The estimated revenues generated in 2019 and 2020 reflect our estimated financial results which were not audited nor reviewed by an independent registered public accounting firm.

Contacts:

Company
NeurAxis, Inc.
info @neuraxis.com

Investor Relations
Gilmartin Group
IR@neuraxis.com

NRXS Investor Presentation:
https://ir.neuraxis.com/news-events/presentations

COMPANY SNAPSHOT
NeurAxis, Inc., is a medical technology company
focused on neuromodulation therapies to address
chronic and debilitating conditions in children and
adults. NeurAxis is dedicated to advancing science
and leveraging evidence-based medicine to drive
adoption of its IB-Stim™ therapy, which is its
proprietary Percutaneous Electrical Nerve Field
Stimulation (PENFS) technology, by the medical,
scientific, and patient communities. IB-Stim™ is FDA
cleared for functional abdominal pain associated
with irritable bowel syndrome (IBS) in adolescents
11-18 years old. Additional clinical trials of PENFS
in multiple pediatric and adult conditions with large
unmet healthcare needs are underway.

$NRXS